Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 14/20 | 0.62 |
| ▸ | CXCL8 | P10145 | 4/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29349773 | 0.97 | CCKBR (0.67) | CCKBRCXCL8 | |
| SCHEMBL23928719 | 0.97 | CCKBR (0.67) | CCKBRCXCL8 | |
| SCHEMBL29362913 | 0.97 | CCKBR (0.67) | CCKBRCXCL8 | |
| SCHEMBL30339999 | 0.92 | CXCL8 (0.60) | CCKBRCXCL8 | |
| SCHEMBL11566228 | 0.91 | PTGS1 (0.56) | CCKBRCXCL8PTGS1 | |
| SCHEMBL30435302 | 0.91 | CXCL8 (0.60) | CCKBRCXCL8 | |
| SCHEMBL29408673 | 0.88 | CCKBR (0.70) | CCKBR | |
| SCHEMBL29360635 | 0.87 | CCKBR (0.57) | CCKBRCXCL8 | |
| SCHEMBL31332293 | 0.84 | PTGS1 (0.61) | PTGS1 | |
| SCHEMBL29369719 | 0.84 | CXCL8 (0.69) | CCKBRCXCL8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120158421-A | Co-differentiated vascularized liver organoid and construction method thereof | 四川大学 | 2025-06-17 | — | — | CN | claimed |
| US-12146155-B2 | Method for constructing human pluripotent stem cell-derived liver organoid having enhanced drug metabolic potential and liver organoid constructed by same method | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-11-19 | — | — | US | claimed |
| US-20220308045-A1 | EXPANDABLE LIVER ORGANOIDS, MEDIA COMPOSITION FOR DIFFERENTIATION THEREOF, AND METHOD FOR PRODUCING LIVER ORGANOIDS USING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2022-09-29 | — | — | US | claimed |
| EP-4728049-A1 | METHODS OF PRODUCING TISSUE-DERIVED EPITHELIAL ORGANOIDS AND USES THEREOF | Genentech, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4707382-A1 | METHOD FOR PRODUCING METABOLICALLY ACTIVATED LIVER ORGANOID, COMPOSITION, AND METHOD FOR EVALUATING TEST SUBSTANCE | JSR Corporation (JP) | 2026-03-11 | — | — | EP | disclosed |
| EP-3565808-B1 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | ARDELYX INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4600349-A1 | STROMAL CELL LAYER AROUND INTESTINAL ORGANOID FOR ENHANCING ENGRAFTMENT AND REGENERATION EFFICACY, AND USE THEREOF | Korea Research Institute of Bioscience and Biotechnology (KR) | 2025-08-13 | — | — | EP | disclosed |
| EP-4585679-A1 | SMALL INTESTINE EPITHELIUM-LIKE CELLS AND PRODUCTION METHOD THEREOF | OSAKA UNIVERSITY (JP) | 2025-07-16 | — | — | EP | disclosed |
| US-20250215058-A1 | ENTEROCOCCUS PORE-FORMING TOXINS AND METHODS OF USE THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250215397-A1 | TWO-DIMENSIONAL CULTURE METHOD HAVING CLEAR CHEMICAL COMPOSITION FOR CULTURING THREE-DIMENSIONAL INTESTINAL ORGANOID-DERIVED INTESTINAL STEM CELL AGGREGATE | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2025-07-03 | — | — | US | disclosed |
| US-20220135949-A1 | HUMAN INTESTINAL EPITHELIUM MODEL AND METHOD FOR PREPARING SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2022-05-05 | — | — | US | disclosed |
| US-11318129-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| EP-3987087-A1 | A GENETIC PHARMACOPEIA FOR COMPREHENSIVE FUNCTIONAL PROFILING OF HUMAN CANCERS | Function Oncology, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20220106354-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| EP-3512935-B1 | METHODS RELATING TO INTESTINAL ORGAN-ON-A-CHIP | HARVARD COLLEGE (US) | 2022-02-23 | — | — | EP | disclosed |
| WO-2022035275-A1 | METHOD FOR MANUFACTURING ORGANOID USING MICROFLUIDIC CHIP | 주식회사 넥스트앤바이오 | 2022-02-17 | — | — | WO | disclosed |
| WO-2022026643-A1 | INTERLEUKIN-22 FUSION PROTEINS, AND THEIR PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS | ANWITA BIOSCIENCES, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| US-20220033454-A1 | INTERLEUKIN-22 FUSION PROTEINS, AND THEIR PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS | ANWITA BIOSCIENCES, INC. (US) | 2022-02-03 | — | — | US | disclosed |
| US-11230603-B2 | Anti-GARP protein | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033454-A1 | INTERLEUKIN-22 FUSION PROTEINS, AND THEIR PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS | IL2, IL36G, ALB | CCKBR 3387/4885CXCL8 79/4885PTGS1 2207/4885 |
| US-20220106354-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | HSD11B2, HSD11B1, NR3C2 | CCKBR 1837/4885CXCL8 3482/4885PTGS1 316/4885 |
| US-11318129-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | CCKBR 426/4885CXCL8 311/4885PTGS1 467/4885 |
| US-20220135949-A1 | HUMAN INTESTINAL EPITHELIUM MODEL AND METHOD FOR PREPARING SAME | VIP, SLC10A2, FABP2 | CCKBR 263/4885CXCL8 1727/4885PTGS1 1119/4885 |
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | CCKBR 426/4885CXCL8 311/4885PTGS1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.